ImmunoMet Therapeutics
BioTech/Drugs - Houston, TX, US
ImmunoMet Therapeutics Employees
ImmunoMet Therapeutics Senior Management
ImmunoMet Therapeutics Details
ImmunoMet Therapeutics is a clinical stage biotech targeting cellular metabolism to develop novel anti-fibrotic and anti-tumor therapies. Our lead molecule, IM156, is a protein complex 1 (PC1) inhibitor that targets the Oxidative Phosphorylation (OXPHOS) pathway in mitochondria and decreases aberrant cell growth in fibrosis and select cancer cells. IM156 is the first potent PC1 inhibitor to complete Phase 1 with a good tolerability. In fibrosis, ImmunoMet is currently conducting a Phase 1 study in healthy volunteers and plan to progress into Phase 2 PoC study in IPF patients in 4Q2021. The company was founded in 2015, is a spin-off from HanAll Biopharma, a Korean midsized public company, and has raised $31 MM post-spin-off.
ImmunoMet Therapeutics Technologies
Email Providers
Gmail
Load Balancers
Apache
Fonts
Google Font API
Hosting
Blue Host
Other
Mobile Friendly